IM Cannabis Raises US$1.2M Convertible Note With 3.94M Warrants and a Quarterly Standby Facility
IMCC is trading near its 52-week low of $0.66 (8.5% above the low).
Summary
IM Cannabis closed a US$1.2 million convertible note (US$1.02 million net after a 15% discount) with 3.94 million warrants at US$0.610 and a ratcheting conversion price floored at US$0.1449, plus an option to sell the investor up to US$1.2 million more per quarter starting January 2027.
Key Events · Financing and Capital Events · IMCC
-
US$1.2M Convertible Note Closed
Principal of US$1,200,000 issued November 4, 2026 with a 15% original issue discount, for net proceeds of US$1,020,000.
-
Warrants and Ratcheting Conversion
3,936,330 warrants at US$0.610 (200% of principal divided by the fixed price) run to November 3, 2029; the note converts at the lower of US$0.610 or 85% of the lowest 20-day VWAP, floored at US$0.1449, and resets lower on dilutive issuances.
-
Quarterly Standby Facility
From January 1, 2027 the company may request additional notes of up to US$1,200,000 per calendar quarter on substantially the same terms, keeping dilution risk open-ended.
-
Repayment and Ownership Caps
The note matures in 28 months with 10 equal monthly installments beginning after month 18, carries 4% interest (14% on default), and is capped at 4.99% beneficial ownership.
Analysis · IMCC · Life Sciences
IM Cannabis closed a US$1.2 million convertible note on November 4, 2026, taking home US$1.02 million after a 15% original issue discount. Conversion is at the lower of US$0.610 or 85% of the lowest 20-day VWAP, floored at US$0.1449, and the deal includes 3,936,330 warrants struck at US$0.610 — roughly 5.5x today's $0.716 price, so the warrants are far out of the money unless the stock recovers. The real weight is the ratchet: any future share issuance below the floor resets the conversion price, so each new raise mechanically hands the holder more shares. Against a market cap near US$1.2 million, this note alone is a company-sized obligation, and the standby facility allowing up to US$1.2 million of additional notes per quarter from January 1, 2027 keeps the dilution tap open. The cash extends runway, but it follows the August and September 2026 convertible notes and the going-concern and Nasdaq delisting warnings previously disclosed — this is survival financing, not growth capital.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.66 to $62.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.